Effective 1 de junho, 2021, implantable continuous glucose monitoring, when using a device considered to be therapeutic, will be considered medically necessary when medical criteria is met for Medicare Advantage plans. Implantable continuous glucose monitoring for commercial products remains not medically necessary. Additionally, modifiers KS and KX representative of non-insulin dependence and insulin dependence respectively, will be required for claims reimbursement. Finally, unit limits are being added to the HCPCS codes for test strips (A4253) and lancets (A4259). Please refer to the medical policy for more details by clicking here.